News No Christmas present for Sanofi, as FDA turns down MS drug FDA has turned down Sanofi's oral BTK inhibitor tolebrutinib for multiple sclerosis, despite suggesting earlier it would delay a decision until 2026.
R&D Beyond good intentions: How life sciences can prove its read... While support for reducing animal use has never been stronger, the path to broad adoption is steep and complex.
News MSD claims two national priority vouchers; report The next two discretionary priority vouchers to be awarded by the FDA are reported to be heading for two MSD drug candidates.
News J&J claims FDA's latest national priority voucher The FDA has awarded its latest national priority voucher to Johnson & Johnson for a combination regimen based on Tecvayli for multiple myeloma.
R&D Future glances: More change, more tech, more harmonisation According to Deloitte’s 2026 Life Sciences Outlook Survey, the life sciences sector might be becoming increasingly borderless, but only 41% of responding biopharma and medtech executives fe
News UK teams up with Singapore on healthtech regulation A partnership between medicines regulators in the UK and Singapore could allow patients in both countries to access new medical advances more quickly.
News Lilly's 'triple G' retatrutide aces crucial obesity trial Lilly's retatrutide achieved weight loss of more than 30% at two years in a new trial, firming up its credentials as a next-generation obesity drug.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.